EUVIMEDEUVIMED entdecken
Crossref

Clinical outcome of acute severe ulcerative colitis – a single center, retrospective study

L Schuster, A Blesl, S Fürst, L Binder, F Baumann-Durchschein, T Fuchs, P Constantini-Kump, W Heimo, C Högenauer

Zeitschrift für Gastroenterologie · 01.05.2025 · 63 (05) · e361

DOI: 10.1055/s-0045-1809271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.05.2025. Verfasst von L Schuster und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition with a mortality rate of approximately 1%. Around one-quarter of ulcerative colitis patients experience at least one episode of ASUC. Material and Methods A retrospective, single center analysis of ASUC-related hospital admissions was conducted from 2004 to 2023. Inclusion criteria were a confirmed diagnosis of ulcerative colitis (UC) or inflammatory bowel disease-unclassified with primary colonic inflammation (IBD-U), hospitalization due to an acute flare, and treatment with either systemic corticosteroids, infliximab, calcineurin-inhibitors, or colectomy. The primary outcomes were response to medical therapy and colectomy rate.

Results

A total of 87 patients (51% females) with 121 hospital admissions were identified. First-line medical therapy was administered in 119 admissions (98%), consisting of prednisolone in 97 (80%), tacrolimus in 13 (11%), and infliximab in 9 (7%) cases. Primary treatment failure, defined as the need for rescue therapy or colectomy, occurred in 38 of 97 (39%) prednisolone, in 1 of 13 (8%) tacrolimus, and in none of the infliximab cases. Second-line medical therapy was applied in 34 of 121 (28%) admissions, comprising calcineurin-inhibitors in 21 (62%; 20 tacrolimus; 1 cyclosporine), and infliximab in 13 (38%) cases. Primary treatment failure was observed in 6 of 21 (29%) calcineurin-inhibitor, and in 2 of 13 (15%) infliximab applications. Colectomy during hospital admission was required in 15 of 87 (17%) patients, performed as first-line therapy in 2 (2%), after failure of first-line medical therapy in 5 (6%), and after failure of second-line medical therapy in 8 (9%) cases. During a median follow-up period of 34 months (IQR 9–80), 25 (29%) patients needed repeated hospitalization and additional 10 (11%) required colectomy.

Conclusion

Despite modern medical therapeutic options, acute colectomy rates in ASUC remain high, therefore newer treatment strategies like JAK-inhibitors or combination therapies should be investigated for this indication. Publication History Article published online: 13 May 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Schuster, L., Blesl, A., Fürst, S., Binder, L., Baumann-Durchschein, F., Fuchs, T., Constantini-Kump, P., Heimo, W., & Högenauer, C. (2025). Clinical outcome of acute severe ulcerative colitis – a single center, retrospective study. Zeitschrift für Gastroenterologie, 63(05), e361. https://doi.org/10.1055/s-0045-1809271

Vancouver

Schuster L, Blesl A, Fürst S, Binder L, Baumann-Durchschein F, Fuchs T, et al. Clinical outcome of acute severe ulcerative colitis – a single center, retrospective study. Zeitschrift für Gastroenterologie. 2025;63(05):e361. doi:10.1055/s-0045-1809271

BibTeX
@article{Schuster2025,
  author = {Schuster, L and Blesl, A and Fürst, S and Binder, L and Baumann-Durchschein, F and Fuchs, T and Constantini-Kump, P and Heimo, W and Högenauer, C},
  title = {Clinical outcome of acute severe ulcerative colitis – a single center, retrospective study},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2025},
  volume = {63},
  number = {05},
  pages = {e361},
  doi = {10.1055/s-0045-1809271}
}
Kostenlos starten →